Ensign has been a dividend-paying company since 2002.

With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase III studies, combining the company’s high-quality ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for ...

Non seulement, cette étude de cohorte prospective confirme qu'un traitement d'arrêt du tabac fondé sur des preuves dans les 6 mois qui suivent un diagnostic de cancer optimise les avantages en termes ...

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient ...

CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of ...

BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Since launching AVISE CTD in 2012, Exagen has produced an extensive body of peer-reviewed literature supporting the test’s clinical validity and utility. These publications and the 1,000,000 th ...

Residents of Olympia Fields and Chicagoland’s surrounding southern suburban communities can now access quality end-of-life care at the VITAS Healthcare Inpatient Hospice Unit at Franciscan Health ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for cancer and autoimmune disease, today ...

The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease (“ADPKD”), and recent peer-reviewed, independent, published research ...

The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 includes strong overall survival, progression-free survival, and durability. This ...